The public health control of scabies: priorities for research and action

Daniel Engelman*, Paul T. Cantey, Michael Marks, Anthony W. Solomon, Aileen Y. Chang, Olivier Chosidow, Wendemagegn Enbiale, Dirk Engels, Roderick J. Hay, D. Hendrickx, Peter J. Hotez, John M. Kaldor, Mike Kama, Charles D. Mackenzie, James S. McCarthy, Diana L. Martin, Birhan Mengistu, Toby Maurer, Nebiyu Negussu, L. RomaniOliver Sokana, Margot J. Whitfeld, L. Claire Fuller, Andrew C. Steer

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    88 Citations (Scopus)


    Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.

    Original languageEnglish
    Pages (from-to)81-92
    Number of pages12
    JournalThe Lancet
    Issue number10192
    Early online date6 Jun 2019
    Publication statusPublished - Jul 2019


    Dive into the research topics of 'The public health control of scabies: priorities for research and action'. Together they form a unique fingerprint.

    Cite this